Repligen Corporation announced that Karen A. Dawes will retire from its Board of Directors effective September 30, 2026, following over twenty years of service. The filing states her departure is not due to any disagreement with the company regarding operations or policies. Repligen operates in the biotechnology industry, providing equipment and services for the development and manufacturing of biological drugs.
